The next ASCO-SITC Clinical Immuno-Oncology Symposium will take place in San Francisco, CA, USA from 25th–27th January 2018. Abstract submission is due to close on Tuesday 3rd October 2017, 11:59pm EDT.
The deadline for Late-Breaking Abstract (LBA) submissions is Tuesday 21st November 2017 at 12:00pm (noon) EDT; however, authors must submit a shell/placeholder abstract by October 3rd to be considered for LBA submission.
The symposium is described as “a three-day meeting focused on clinical and translational research in immune-oncology and the implications for clinical care” and aims to “address the high-level need for clinical education in a field where all aspects of care are fundamentally different from traditional therapies.” The program will offer insights into the use of immunotherapy in hematologic malignancies, as well as in melanoma, lung cancer, and solid tumors through a varied number of sessions including Keynote Lectures, early morning “Immunology 101” talks, “Networking Roundtable” opportunities, and “Evening Highlights” sessions.
Subcategories within the Hematologic Malignancies category include: biomarkers and inflammatory signatures, cell therapies, humoral immunity for diagnosis and therapy, immune checkpoints and stimulatory receptors, and modulating innate immunity.
For more information on abstract submission guidelines, visit: http://immunosym.org/abstracts/abstract-submission-guidelines